These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35345962)

  • 41. Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques.
    Hel Z; Nacsa J; Tsai WP; Thornton A; Giuliani L; Tartaglia J; Franchini G
    Virology; 2002 Dec; 304(1):125-34. PubMed ID: 12490410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit.
    Valentin A; von Gegerfelt A; Rosati M; Miteloudis G; Alicea C; Bergamaschi C; Jalah R; Patel V; Khan AS; Draghia-Akli R; Pavlakis GN; Felber BK
    Vaccine; 2010 Feb; 28(8):1962-74. PubMed ID: 20188252
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques.
    Halwani R; Boyer JD; Yassine-Diab B; Haddad EK; Robinson TM; Kumar S; Parkinson R; Wu L; Sidhu MK; Phillipson-Weiner R; Pavlakis GN; Felber BK; Lewis MG; Shen A; Siliciano RF; Weiner DB; Sekaly RP
    J Immunol; 2008 Jun; 180(12):7969-79. PubMed ID: 18523260
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced Cross-Reactive and Polyfunctional Effector-Memory T Cell Responses by ICVAX-a Human PD1-Based Bivalent HIV-1 Gag-p41 Mosaic DNA Vaccine.
    Chen SMY; Wong YC; Yim LY; Zhang H; Wang H; Lui GCY; Li X; Tang X; Cheng L; Du Y; Peng Q; Wang J; Kwok HY; Huang H; Lau TT; Chan DPC; Wong BCK; Liu L; Chakrabarti LA; Lee SS; Chen Z
    J Virol; 2022 Apr; 96(7):e0216121. PubMed ID: 35297660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination.
    Hu X; Valentin A; Cai Y; Dayton F; Rosati M; Ramírez-Salazar EG; Kulkarni V; Broderick KE; Sardesai NY; Wyatt LS; Earl PL; Moss B; Mullins JI; Pavlakis GN; Felber BK
    Hum Gene Ther; 2018 Sep; 29(9):1029-1043. PubMed ID: 29869530
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.
    Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protection against SHIV-KB9 infection by combining rDNA and rFPV vaccines based on HIV multiepitope and p24 protein in Chinese rhesus macaques.
    Li C; Shen Z; Li X; Bai J; Zeng L; Tian M; Song YJ; Ye M; Du S; Ren D; Liu C; Zhu N; Sun D; Li Y; Jin N
    Clin Dev Immunol; 2012; 2012():958404. PubMed ID: 22474488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques.
    Li J; Valentin A; Kulkarni V; Rosati M; Beach RK; Alicea C; Hannaman D; Reed SG; Felber BK; Pavlakis GN
    Vaccine; 2013 Aug; 31(36):3747-55. PubMed ID: 23624057
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
    Qureshi H; Ma ZM; Huang Y; Hodge G; Thomas MA; DiPasquale J; DeSilva V; Fritts L; Bett AJ; Casimiro DR; Shiver JW; Robert-Guroff M; Robertson MN; McChesney MB; Gilbert PB; Miller CJ
    J Virol; 2012 Feb; 86(4):2239-50. PubMed ID: 22156519
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.
    Hancock G; Morón-López S; Kopycinski J; Puertas MC; Giannoulatou E; Rose A; Salgado M; Hayton EJ; Crook A; Morgan C; Angus B; Chen F; Yang H; Martinez-Picado J; Hanke T; Dorrell L
    J Int AIDS Soc; 2017 May; 20(1):21171. PubMed ID: 28537062
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preventing AIDS but not HIV-1 infection with a DNA vaccine.
    Shen X; Siliciano RF
    Science; 2000 Oct; 290(5491):463-5. PubMed ID: 11183769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials.
    Hanke T
    Expert Rev Vaccines; 2019 Oct; 18(10):1029-1041. PubMed ID: 31613649
    [No Abstract]   [Full Text] [Related]  

  • 53. Initiation of Antiretroviral Therapy Restores CD4+ T Memory Stem Cell Homeostasis in Simian Immunodeficiency Virus-Infected Macaques.
    Cartwright EK; Palesch D; Mavigner M; Paiardini M; Chahroudi A; Silvestri G
    J Virol; 2016 Aug; 90(15):6699-6708. PubMed ID: 27170752
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.
    Knudsen ML; Mbewe-Mvula A; Rosario M; Johansson DX; Kakoulidou M; Bridgeman A; Reyes-Sandoval A; Nicosia A; Ljungberg K; Hanke T; Liljeström P
    J Virol; 2012 Apr; 86(8):4082-90. PubMed ID: 22318135
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New gene-based approaches for an AIDS vaccine.
    Puaux AL; Michel ML
    Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):357-72. PubMed ID: 12818622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption.
    Ziani W; Shao J; Wang X; Russell-Lodrigue K; Liu YZ; Montaner LJ; Veazey RS; Xu H
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33408173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy.
    de Jong W; Aerts J; Allard S; Brander C; Buyze J; Florence E; van Gorp E; Vanham G; Leal L; Mothe B; Thielemans K; Plana M; Garcia F; Gruters R;
    Trials; 2019 Jun; 20(1):361. PubMed ID: 31208472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Towards an AIDS vaccine: the role of primate models.
    Nathanson N
    Int J STD AIDS; 1998; 9 Suppl 1():3-7. PubMed ID: 9874107
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction of CD8+ cells able to suppress CCR5-tropic simian immunodeficiency virus SIVmac239 replication by controlled infection of CXCR4-tropic simian-human immunodeficiency virus in vaccinated rhesus macaques.
    Tsukamoto T; Yuasa M; Yamamoto H; Kawada M; Takeda A; Igarashi H; Matano T
    J Virol; 2007 Nov; 81(21):11640-9. PubMed ID: 17728225
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys.
    Borducchi EN; Cabral C; Stephenson KE; Liu J; Abbink P; Ng'ang'a D; Nkolola JP; Brinkman AL; Peter L; Lee BC; Jimenez J; Jetton D; Mondesir J; Mojta S; Chandrashekar A; Molloy K; Alter G; Gerold JM; Hill AL; Lewis MG; Pau MG; Schuitemaker H; Hesselgesser J; Geleziunas R; Kim JH; Robb ML; Michael NL; Barouch DH
    Nature; 2016 Dec; 540(7632):284-287. PubMed ID: 27841870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.